| NCT06998056 | Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis | RECRUITING | PHASE2 | 2025-06-09 | 2026-06 | 2026-06 |
| NCT05028582 | Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) | COMPLETED | PHASE3 | 2021-08-24 | 2022-06-03 | 2022-06-03 |
| NCT04973228 | Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) | COMPLETED | PHASE3 | 2021-07-08 | 2022-04-06 | 2022-04-06 |
| NCT04845620 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) | COMPLETED | PHASE3 | 2021-04-07 | 2023-06-01 | 2023-06-01 |
| NCT04811131 | Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo | TERMINATED | PHASE2 | 2021-03-04 | 2021-08-09 | 2021-08-09 |
| NCT04746911 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) | COMPLETED | PHASE2 | 2021-03-01 | 2022-05-11 | 2022-05-11 |
| NCT04804605 | Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis | COMPLETED | PHASE3 | 2021-02-25 | 2024-05-28 | 2024-05-28 |
| NCT04773600 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) | COMPLETED | PHASE3 | 2021-02-24 | 2022-09-29 | 2022-09-29 |
| NCT04773587 | Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis | COMPLETED | PHASE3 | 2021-01-27 | 2022-08-30 | 2022-08-30 |
| NCT04655313 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) | COMPLETED | PHASE2 | 2020-11-30 | 2022-01-12 | 2022-01-12 |
| NCT04445987 | Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | COMPLETED | PHASE2 | 2020-06-12 | 2022-11-19 | 2022-11-19 |
| NCT04378569 | Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema | COMPLETED | PHASE1, PHASE2 | 2020-04-20 | 2021-02-24 | 2021-02-24 |
| NCT04279119 | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis | COMPLETED | PHASE1 | 2020-03-10 | 2021-03-25 | 2021-03-25 |
| NCT04286607 | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | COMPLETED | PHASE3 | 2020-02-12 | 2024-01-22 | 2024-01-22 |
| NCT04128007 | Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis | COMPLETED | PHASE2 | 2020-01-13 | 2020-09-25 | 2020-09-23 |
| NCT04156191 | Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema | COMPLETED | PHASE1 | 2019-12-23 | 2023-05-02 | 2023-05-02 |
| NCT04211363 | Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | COMPLETED | PHASE3 | 2019-12-20 | 2020-11-16 | 2020-11-16 |
| NCT04211389 | Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | COMPLETED | PHASE3 | 2019-12-17 | 2020-11-23 | 2020-11-23 |
| NCT04091646 | Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | COMPLETED | PHASE2 | 2019-12-04 | 2020-08-21 | 2020-08-18 |
| NCT03916081 | Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis | COMPLETED | PHASE2 | 2019-05-31 | 2019-11-04 | 2019-11-04 |
| NCT03764475 | Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis | COMPLETED | PHASE2 | 2018-12-18 | 2020-10-08 | 2020-10-08 |
| NCT03638258 | The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis | COMPLETED | PHASE2 | 2018-09-21 | 2019-05-29 | 2019-05-29 |
| NCT03392168 | Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis | COMPLETED | PHASE1, PHASE2 | 2017-12-11 | 2018-05-02 | 2018-05-02 |